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Abstract
Human mitochondrial ornithine transporter-1 is reported in coupling with the hyperornithinemia-hyperammonemia-
homocitrullinuria (HHH) syndrome, which is a rare autosomal recessive disorder. For in-depth understanding of the
molecular mechanism of the disease, it is crucially important to acquire the 3D structure of human mitochondrial ornithine
transporter-1. Since no such structure is available in the current protein structure database, we have developed it via
computational approaches based on the recent NMR structure of human mitochondrial uncoupling protein (Berardi MJ,
Chou JJ, et al. Nature 2011, 476:109–113). Subsequently, we docked the ligand L-ornithine into the computational structure
to search for the favorable binding mode. It was observed that the binding interaction for the most favorable binding mode
is featured by six remarkable hydrogen bonds between the receptor and ligand, and that the most favorable binding mode
shared the same ligand-binding site with most of the homologous mitochondrial carriers from different organisms, implying
that the ligand-binding sites are quite conservative in the mitochondrial carriers family although their sequences similarity is
very low with 20% or so. Moreover, according to our structural analysis, the relationship between the disease-causing
mutations of human mitochondrial ornithine transporter-1 and the HHH syndrome can be classified into the following three
categories: (i) the mutation occurs in the pseudo-repeat regions so as to change the region of the protein closer to the
mitochondrial matrix; (ii) the mutation is directly affecting the substrate binding pocket so as to reduce the substrate
binding affinity; (iii) the mutation is located in the structural region closer to the intermembrane space that can significantly
break the salt bridge networks of the protein. These findings may provide useful insights for in-depth understanding of the
molecular mechanism of the HHH syndrome and developing effective drugs against the disease.
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Introduction
The hyperornithinemia-hyperammonemia-homocitrullinuria
(HHH) syndrome (MIM 238970), also called ‘‘ornithine translo-
cation deficiency’’, is a rare autosomal recessive disorder,
characterized by mental retardation, progressive spastic parapa-
resis, seizures, and myoclonus epilepsy [1,2]. This kind of disease
varies widely in its severity and age of onset. An infant with HHH
syndrome may refuse to eat, or have poorly controlled breathing
rate or body temperature. Some babies with this disorder may
experience unusual body movements, or go into a coma [3,4].
These disease signs and symptoms for most affected individuals do
not appear until later in life. Late-onset forms of HHH syndrome
are usually less severe than the infantile forms. Some people with
late-onset HHH syndrome cannot tolerate high-protein foods. In
some cases, high-protein meals or prolonged periods without food
may cause ammonia to accumulate more quickly in the blood [5].
This rapid increase of ammonia may lead to episodes of vomiting,
lack of energy, problems with coordination, confusion, or blurred
vision. Complications of HHH syndrome may include develop-
mental delay, learning disabilities, and stiffness caused by
abnormal tensing of the muscles [3,6].
The HHH syndrome is thought to be caused by the defective
activities of the mitochondrial carrier responsible for transporting
ornithine from the cytoplasm into the inner mitochondrial
membrane [7]. Mutations of the solute carrier family 25
(mitochondrial ornithine transporter) member 15 (SLC25A15)
gene (previously termed ORNT1) have been shown to be
correlated with the HHH syndrome [8]. This gene encodes the
mitochondrial ornithine transporter-1 that catalyzes the electro-
neutral exchange of ornithine for proton. The members of
mitochondrial carrier family are mainly located in the inner
mitochondrial membrane and allow exchange of substrates
between the cytosol and the mitochondrial matrix. Mitochondrial
carriers link the biochemical pathways of the cytosol and the
mitochondrial matrix by transporting metabolites, nucleotides,
inorganic ions, and vitamins across the mitochondrial inner
membrane [9,10]. These transport steps are essentially required
for many biochemical processes, such as the synthesis of haem and
iron-sulphur clusters, the synthesis of ATP from the oxidation of
sugars and fats, production of heat, oxidative phosphorylation,
amino acids and fatty acid synthesis and degradation, as well as the
replication, transcription and translation of the mitochondrial
genome [9,10,11].
Stimulated by the recent success in determining the 3D (three-
dimensional) structure of the mitochondrial uncoupling protein 2
by NMR [12], the present study was initiated in an attempt to
reveal the action mechanism of HHH syndrome by investigating
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transporter-1. In this study, we attempted to study the structures of
wild-type and mutated mitochondrial ornithine transporter-1 by
molecular modeling approaches, with an aim of providing detailed
mechanism for HHH syndrome. As no structural information
available in the protein structure databases, we firstly employed
computational approach to construct a three-dimensional struc-
tural model for mitochondrial ornithine transporter-1. Subse-
quently, we employed flexible molecular docking operations to
identify substrate binding site in mitochondrial ornithine trans-
porter-1 followed by molecular dynamics simulations to optimize
these structural models. Based on these computational studies,
structural analysis was carried out to get detailed information for
HHH syndrome.
Materials and Methods
1. Molecular Modeling
The entire sequence of human mitochondrial ornithine
transporter-1 (encoded by human SLC25A15 gene), which contains
301 amino acids, was taken from the UniProt Database with an
accession number of Q9Y619. The secondary structure of this
protein was predicted by the membrane protein secondary
structure prediction tool SPLIT4 [13]. To identify template
proteins having similar folding structure or structural motif from
Protein Data Bank, eight threading algorithms (MUSTER [14],
FUGUE [15], HHSEARCH [16], PROSPECT [17], COMA
[18], SP3 [19], SAM [20], and SPARKS [21]) were used to
search the PDB library for those structures which have the
similar sequence and secondary structures with the human
mitochondrial ornithine transporter-1. The three top template
hits obtained with the aforementioned eight threading algo-
rithms were then selected to perform multiple sequence
alignment (Fig. 1). Based on the template structures and
multiple sequence alignment, the 3D structure of human
mitochondrial ornithine transporter-1 was derived by the
‘‘segment matching’’ or ‘‘coordinate reconstruction’’ approach
[22] and ab initio modeling [23]. The former was used to predict
the aligned region structures based on the template fragments,
whereas the latter was employed to construct the unaligned
region structures. The segment matching approach had been
successfully used to model the 3D structures of cytochrome P450
enzymes [24,25], New Delhi metallo-beta-lactamse [26], and
xylose reductases [27] before their crystal structures were
available, timely providing useful information for both basic
research and drug development in the relevant areas.
Figure 1. The multiple sequence alignment of the target protein with its three template structures. The target protein is human
mitochondrial ornithine transporter-1; the three templates are 2lck.pdb, 2c3e.pdb, and 1okc.pdb. The amino acids are colored according to the
following 7 types: (i) acidic, red; (ii) basic, dark blue; (iii) neutral hydrophilic, pink; (iv) aliphatic, green; (v) aromatic, light green; (vi) thiol-containing,
yellow; (vii) imino, organ. The sequence similarity scores of the target protein with 2lck.pdb, 2c3e.pdb, and 1okc.pdb are 26%, 21%, and 20%,
respectively.
doi:10.1371/journal.pone.0031048.g001
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Computational docking operation is a useful vehicle for
investigating the interaction of a protein receptor with its ligand
and revealing their binding mechanism as demonstrated by a
series of studies [28,29,30]. In this study, based on the
computational structure model, molecular docking operations
were carried out with Monte Carlo simulated annealing to get the
favorable binding modes for human mitochondrial ornithine
transporter-1 with L-ornithine. The present strategy consists of
two stages: (1) development of the 3D structure of the protein
receptor with the aforementioned techniques, and (2) investigation
into the protein-ligand interactions by the techniques of molecular
docking and molecular dynamics. A similar strategy has also been
adopted by Gonzalez-Diaz et al. [31,32,33] recently. These
authors used the program Hyperchem and/or the web server
LOMETS [34] for stage (1). Furthermore, instead of molecular
docking, they used the method MARCH-INSIDE to predict
protein-ligand interactions (including protein-drug or protein-
protein interactions) [31,32,33]. The method used by Gonzalez-
Diaz et al. allowed them to develop new protein-ligand interaction
servers like MIND-BEST, NL MIND-BEST, MISS-Prot, etc.
However, these kinds of web servers could only yield the protein-
ligand interaction scores for large-scale datasets without providing
us with the detailed interactive geometry for some specific cases as
concerned in the current study. The potential binding site was
identified using Q-SiteFinder [35]. Since ligand binding in the
active site might induce some conformational changes [36,37,38],
a flexible docking procedure was adopted to construct the binding
modes as described below. Before conducting molecular docking,
we extracted 10,000 different configurations of human mitochon-
drial ornithine transporter-1 from a short-time molecular dynam-
ics simulation as initial structures. The ligand was then docked into
all these configurations to search for the favorable binding modes
using the genetic algorithm, and the best 100 modes were taken for
the further analyses. The docking program [39] used in this study
would automatically generate a diversified set of configurations by
randomly changing the atomic coordinates of the ligand. When a
new configuration of the ligand was generated, the search for the
favorable binding mode was operated within a specified 3D box by
the simulated annealing to optimize the purely spatial contacts as
well as electrostatic interactions. Finally, the favorable binding
mode thus obtained was further optimized by a short-time
molecular dynamics simulation. During the docking procedure,
the Merck force field parameters were adopted, and the binding
modes were assessed by a scoring function London dG [40].
3. Molecular Dynamics
Many marvelous biological functions in proteins and DNA and
their profound dynamic mechanisms can be revealed by studying
their internal motions [41,42]. Likewise, to really understand the
action mechanism of human mitochondrial ornithine transporter-
1 with its ligands, we should consider not only the static structures
concerned but also the dynamical information obtained by
simulating their internal motions or dynamic process. In view of
this, it is necessary to further perform a molecular dynamic
simulation for the favorable binding mode obtained by the
molecular docking operation as described above. Here the
molecular dynamics simulations were performed by GROMACS
3.3.1 with GROMACS force field parameters [43], the periodic
boundary conditions, and NPT ensembles. The topology file, force
field parameters, as well as charges for the ligand were generated
by online tool PRODRG [44]. Before starting simulations, the
structural model was merged with a patch of a pre-equilibrated
membrane with 256 DPPC bilayers from our previous studies
[45], and subsequently solvated with explicit simple point charge
(SCP) waters embedded in the simulation box. Meanwhile, sodium
ions were randomly placed to neutralize the simulating system.
The simulating system was then subjected to a 3000-step energy
minimization with the steepest descents approach followed by
conjugated gradient for the next 2000 steps. Finally, 1-ns
molecular dynamics simulations were performed at 310 K. During
our simulations, all bonds were constrained by the LINear
Constraint Solver (LINCS) algorithm and atom velocities for
start-up runs were obtained according to a Maxwell distribution at
310 K [46,47]. To maintain the simulating system at a constant
temperature and pressure, the Berdensen thermostat was applied
with a coupling time of 0.1 and 1.0 ps [48]. The particle mesh
Ewald algorithm was employed to treat electrostatic interactions
with interpolation order of 4 and a grid spacing of 0.12 [49]. The
van der Waals interactions were treated by using a cutoff of 12 A ˚.
The integration step is 1 fs, and the coordinates were saved every 1
ps.
Results and Discussion
1. Computational Model
One of the most important procedures in modeling the 3D
structure of a protein is how to identify or select the template
structure. For the current case, none of the structure-known
proteins in the Protein Data Bank has more than 30% sequence
similarity with the human mitochondrial ornithine transporter-1.
Under such a circumstance, it is not feasible to use the
conventional homology modeling technique to derive the 3D
structure of human mitochondrial ornithine transporter-1. To
overcome such a difficulty, we resorted to the threading approach.
After eight different threading operations were carried out, we
found the following three template structures from the Protein
Data Bank: (1) 2lck.pdb [12], (2) 2c3e.pdb [50], and (3) 1okc.pdb
[51]. Subsequently, the sequences of the three template structures
and the sequence of the human mitochondrial ornithine
transporter-1 were subject to the multiple sequence alignment,
as shown in Fig. 1. It was found from the alignment that the
sequence similarity scores of the target protein with the three
template proteins were 26% (for 2lck.pdb), 21% (for 2c3e.pdb),
and 20% (for 1okc.pdb), respectively. In other words, none of the
three structural templates has more than 30% sequence identity
with the target protein. Under such a circumstance, we had to use
Figure 2. The 3D computational structure for the human
mitochondrial ornithine transporter-1. (A) Viewed from the side to
see more of its loops. (B) Viewed from the matrix side of the carrier to
see more of its ‘‘repeat three’’.
doi:10.1371/journal.pone.0031048.g002
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information for constructing the structure of human mitochondrial
ornithine transporter-1. The concrete procedures were to divide
the original sequence of human mitochondrial ornithine trans-
porter-1 into a number of short segments with each containing 6
amino acids, followed by aligning these segments into all the three
structural templates. Based on the sequence alignment of Fig. 1
and the template structures, the threading aligned region of the
target protein was constructed. As for the threading unaligned
region, the corresponding structure was derived with the ab initio
approach. The entire 3D structure thus obtained for the human
mitochondrial ornithine transporter-1 is shown in Fig. 2.
To validate the computational structure, the following exam-
inations were performed. The stereochemistry and structural
features were examined by PROCHECK [52]. It was indicated by
PROCHECK that 90.4% residues of the computational structure
were located in the ‘‘core’’ region, 7.2% in the ‘‘allowed’’ region,
1.6% in the ‘‘general’’ region, and only 0.8% in the ‘‘disallowed’’
region (Fig. 3). For a good quality model, the residues located in
the core and allowed regions should be expected to be over 90%,
which is the case for our model since 90.4%+7.2%=97.6%.
Moreover, for its main-chain residues, all the bond lengths and
94.0% of the bond angles are within the allowed limits. To further
examine our computational model of human mitochondrial
ornithine transporter-1, we also used the tool of QMEAN, which
is a scoring function of a linear combination of 6 structural
descriptors (Cb interaction energy, all-atom pairwise energy,
salvation energy, torsion angle energy, secondary structure, and
solvent accessibility) [53]. The QMEAN score ranges between 0
and 1 with higher value to reflect a better quality of the input
model. The QMEAN score for our current model is 0.682.
Another tool ANOLEA [54] was also involved in examining the
local model quality, and the result thus obtained was in good
accord with the results by PROCHECK and QMEAN, indicating
that most of the residues in the computational model were located
in the favorable regions. Furthermore, we also used DFIRE [55] to
evaluate the global model quality. Based on a distance-scaled finite
ideal-gas reference state, DFIRE can be used to assess the non-
bonded atomic interactions in the protein model. It can provide
the pseudo energies for the computational model to reflect its
quality. The result by DFIRE on our computational model was -
366.03, indicating that it was quite close to the native
conformation. All these validated results indicate that our
computational model is quite reliable.
2. Substrate Binding
As expected, the computational structure is a channel-like one
(Fig. 2A), in which the three pseudo-repeats adopted the similar
folding pattern as those in the human UCP2 [12] and bovine
ADP/ATP carrier [51]. Each pseudo repeat contained a
transmembrane helix (TMH), a loop, an amphipathic helix
(APH), and a second transmembrane helix (Fig. 2B). The
Figure 3. Ramachandran plot for the computational model of human mitochondrial ornithine transporter-1. It was derived from the
plot that 90.4% residues located in the core region, 7.2% in the allowed region, 1.6% in the general region, and only 0.8% in the disallowed region.
For a good quality model, the residues located in the core and allowed regions should be more than 90%, which is the case for our model since
90.4%+7.2%=97.6%.
doi:10.1371/journal.pone.0031048.g003
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carrier further indicates that the members in the mitochondrial
carrier family have a conserved folding structure and that the
variations within this conserved fold frame would govern the
specificity of substrate binding and translocation.
Based on the computational model, we docked L-orinithine into
human mitochondrial ornithine transporter-1 with the scoring
function of London dG to assess the binding interactions, and the
most favorable binding mode thus found is shown in Fig. 4A.
Among the 10,000 configurations investigated for the protein, only
the binding mode was selected that had the correct chemistry and
geometry for it to bind the substrate. The corresponding binding
pocket thus identified is quite similar to the ones in yeast
mitochondrial carriers that were reported to have the conserved
substrate binding sites [56,57]. Like the yeast mitochondrial
carriers, the residues involved in such substrate-binding mode
were quite conservative in these homologous carriers since they,
although from different organisms, have the same function [57]. It
is interesting to see from the most favorable binding mode of
human mitochondrial ornithine transporter-1 with L-orinithine
that six remarkable hydrogen bonds were observed (Fig. 4B). For
the detailed information of the six hydrogen bonds, see Table 1.
These hydrogen bonds, especially the one formed by Arg275, were
thought to play crucial roles for the substrate in recognizing its
receptor and performing proper binding.
Figure 4. Binding model of L-ornithine bound to human
mitochondrial ornithine transporter-1. (A) Lateral view of the
ornithine binding interactions, where the backbone of human
mitochondrial ornithine transporter-1 is colored in coffee, while the
ligand L-ornithine in green. (B) A close view of the binding interactions
for more detailed information.
doi:10.1371/journal.pone.0031048.g004
Table 1. Detailed information for the hydrogen bonding
formed by human mitochondrial ornithine transporter-1 and
its substrate L-ornithine.
H-donor H-receptor Bond dist (A ˚) Lifetime (%)
L-ornithine (Ob) Asp31 2.17 31.1
L-ornithine (Ob) Gln135 2.67 33.9
Arg275 L-ornithine (NH2) 2.56 40.4
Lys131 L-ornithine (Ob) 2.86 56.0
L-ornithine (NH2) Asp31 2.55 73.0
Lys34 L-ornithine (NH2) 2.60 96.8
doi:10.1371/journal.pone.0031048.t001
Figure 5. A schematic drawing to summarize the 16 missense
mutations of human mitochondrial ornithine transporter-1 in
the HHH syndrome. The backbone structure of the protein is colored
in purple with the ribbon drawing, while its mutation parts in coffee
with the spacing filling drawing. The L-ornithine is in red with the stick
drawing.
doi:10.1371/journal.pone.0031048.g005
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A total of 16 missense mutations involving 15 amino acids within
human mitochondrial ornithine transporter-1 have been reported
from the HHHsyndrome patients [8,58,59,60,61,62,63,64]. Shown
in Fig. 5 is the distribution of the aforementioned 16 missense
variants when mappedonto ourcomputational model.Based onthe
aforementioned computational analysis, these 16 missense variants
can be divided into three classes. The first class of the mutations
occurs in the three pseudo-repeats (M37R and I254L). The disease-
causing mutations in this category may change the folding structure
of the pseudo-repeats that are conserved in the mitochondrial
family, further altering the structure of mitochondrial matrix to
cause the dysfunction of the protein. The mutations in the second
class (G27E/G27R, A70L, L71Q, P126R, E180K, T272I, M273K,
and R275Q) may directly affect the structures of substrate binding
pocket. G27E/G27R, A70L, and L71Q may have a deleterious
impact on the hydrogen bonding of Asp31, Lys34, Lys131, and
Gln135. R275Q can break a significant hydrogen bond, which may
also be influenced by T272I and M273K. The third class of
mutations is involved with G113C, F188L, G190D, G216S, and
L283F. These residues are located in the cytoplasmic domain near
the lipid bilayers, and are thought to form salt bridge networks to
control the channel opening and substrate translocation [65].
In conclusion, we have developed a 3D structure for human
mitochondrial ornithine transporter-1 based on 2lck.pdb, the
NMR structure of human mitochondrial uncoupling protein 2, as
well as 2c3e.pdb and 1okc.pdb, the crystal structures of the bovine
ADP/ATP carriers. The examinations by PROCHECK and
QMEAN have indicated that the computed structure is quite
reliable. It was observed by docking L-ornithine into the human
mitochondrial ornithine transporter-1 that the binding mode was
featured by six remarkable hydrogen bonds between the receptor
and ligand. The relationship between the mutations of human
mitochondrial ornithine transporter-1 and the HHH syndrome
was analyzed. According to their different locations, the disease-
causing mutations can be categorized into the following three
types: the first type is that the mutation occurs in the pseudo-
repeat regions so as to change the mitochondrial matrix structure
of the protein; the second type is directly affecting the substrate
binding pocket so as to reduce the substrate binding affinity; the
third type is for the mutation located in the cytoplasmic domain
that can significantly break the salt bridge networks of the protein.
These findings may provide useful insights for understanding the
molecular mechanism of causing the HHH syndrome.
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